Company: SCLXW
Filing Date: 2025-05-14
Form Type: 424B3
Source: 0001193125-25-119846
Chunk: 189

Company: Scilex Holding Co
Filing Date: 2025-05-14
Form: 424B3
Chunk 189
---
 elsewhere in this
prospectus.

Other (Income) Expense

(Gain) loss on Derivative Liability

(Gain) loss on derivative liability includes the remeasurement of the derivative warrant liability. See
Note 4 titled “Fair Value Measurements” to our consolidated financial statements appearing elsewhere in this prospectus.

Change in Fair Value of Debt and Liability Instruments

Change in fair value of debt and liability instruments includes the remeasurement of
(i) the convertible debentures (the “Convertible Debentures”) issued to YA II, Ltd. (“Yorkville”) pursuant to that certain securities purchase agreement dated as of March 21, 2023 and amended on October 11, 2023,
between Yorkville and us, (ii) the Oramed Note, (iii) the non-refundable deposit in the aggregate principal amount of $10.0 million (the “FSF Deposit”) pursuant to the Commitment
Letter dated as of June 11, 2024, entered into with FSF, (iv) the Tranche B Notes issued in October 2024 in the principal amount of $50.0 million and (v) the purchased revenue liability associated with the ZTlido Royalty Purchase
Agreement with certain institutional investors (collectively, the “ZTlido Royalty Investors”) and Oramed. See Note 4 titled “Fair Value Measurements” to our consolidated financial statements appearing elsewhere in this
prospectus.

Interest Expense, Net

Interest expense, net consists of interest related to the loans in an aggregate principal amount of up to $30.0 million (the
“Revolving Facility”) made available by eCapital Healthcare Corp. pursuant to a Credit and Security Agreement (the “eCapital Credit Agreement”) that Scilex Pharma entered into on June 27, 2023.

Loss on Foreign Currency Exchange

Loss
on foreign currency exchange relates to foreign exchange losses on payments made to our foreign supplier, Itochu, a manufacturer and supplier of lidocaine tape products, including ZTlido and SP-103.

118

Results of Operations The following tables summarize our results of operations for the years ended December 31, 2024 and 2023 (in thousands):

|                                                        |     | Year Ended December 31, |    2024 |   |     |   |     2023 |   |     |   | Changes |   |
|:-------------------------------------------------------|:----|:------------------------|--------